Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats
Introduction Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims...
Saved in:
| Published in | BMC complementary and alternative medicine Vol. 21; no. 1; p. 301 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
20.12.2021
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2662-7671 2662-7671 1472-6882 |
| DOI | 10.1186/s12906-021-03472-2 |
Cover
| Abstract | Introduction
Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats.
Methods
Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis.
Results
BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH.
Conclusion
This study demonstrated that BBR could significantly prevent the development of BPH in rats. |
|---|---|
| AbstractList | Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats. Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis. BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1[beta] and tumor necrosis factor [alpha]) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH. This study demonstrated that BBR could significantly prevent the development of BPH in rats. INTRODUCTION: Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats. METHODS: Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis. RESULTS: BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH. CONCLUSION: This study demonstrated that BBR could significantly prevent the development of BPH in rats. Introduction Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats. Methods Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis. Results BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1[beta] and tumor necrosis factor [alpha]) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH. Conclusion This study demonstrated that BBR could significantly prevent the development of BPH in rats. Keywords: Berberine, BPH, Testosterone, Oxidative stress, Inflammation, Rat Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats. Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis. BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH. This study demonstrated that BBR could significantly prevent the development of BPH in rats. Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats.INTRODUCTIONBenign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats.Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis.METHODSAnimals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis.BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH.RESULTSBBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH.This study demonstrated that BBR could significantly prevent the development of BPH in rats.CONCLUSIONThis study demonstrated that BBR could significantly prevent the development of BPH in rats. Introduction Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats. Methods Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis. Results BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH. Conclusion This study demonstrated that BBR could significantly prevent the development of BPH in rats. Abstract Introduction Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats. Methods Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis. Results BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH. Conclusion This study demonstrated that BBR could significantly prevent the development of BPH in rats. |
| ArticleNumber | 301 |
| Audience | Academic |
| Author | Kalantar, Hadi Shabani, Ehsan Goudarzi, Mehdi Kalantari, Heibatullah Kalantar, Mojtaba Mansouri, Esrafil |
| Author_xml | – sequence: 1 givenname: Ehsan surname: Shabani fullname: Shabani, Ehsan organization: Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences – sequence: 2 givenname: Heibatullah surname: Kalantari fullname: Kalantari, Heibatullah organization: Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences – sequence: 3 givenname: Mojtaba surname: Kalantar fullname: Kalantar, Mojtaba organization: Shoushtar Faculty of Medical Sciences, Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences – sequence: 4 givenname: Mehdi surname: Goudarzi fullname: Goudarzi, Mehdi organization: Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences – sequence: 5 givenname: Esrafil surname: Mansouri fullname: Mansouri, Esrafil organization: Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences – sequence: 6 givenname: Hadi surname: Kalantar fullname: Kalantar, Hadi email: kalantar-h@ajums.ac.ir organization: Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Department of Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34930229$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkltr3DAQhU1JadI0f6APxVAofXGqm2XppZCGXgKhfWmfhSyPdhW80layA_n3nc2myW4ooRhjI33nzGh0XlYHMUWoqteUnFKq5IdCmSayIYw2hIuONexZdcSkZE0nO3qw839YnZRyRQhhnPKOty-qQy40J4zpo-r7J8g95BChtisYQ8p2glLjO6UyQcaiTYjD7GCoe4hhEet1xh2k6uXNGvJ6tCXYOsQaleVV9dzbscDJ3fe4-vXl88_zb83lj68X52eXjcOGpoYpq-jgFRe-lQPvuRXeK80cCN9ZYSWhggy988JLaVsJWgrlndOCAGe-5cfVxdZ3SPbKrHNY2Xxjkg3mdiHlhbF5Cm4EoyQDZxmxlLQC1b0Y9NALxTjpoFcKvT5uvdZzv4LBQZyyHfdM93diWJpFukZnTQTjaPD-ziCn3zNOzqxCcTCONkKai2GSS66YVN1_oJTxTqlu09bbR-hVmnPEqSLFiG5FS8gDtbB41hB9whbdxtScSc0lcp1G6vQfFD4DrILDO_YB1_cE73YES7DjtCxpnKeQYtkH3-wO735qfxOGANsCDmNTMvh7hBKzSbLZJtlgks1tkg1DkXokcgEjh8Wx7zA-LeVbacE6cQH5YWxPqP4A6KgFKQ |
| CitedBy_id | crossref_primary_10_1016_j_ejphar_2023_175762 crossref_primary_10_1007_s00784_024_05540_6 crossref_primary_10_1016_j_ijpharm_2024_124892 crossref_primary_10_1007_s00210_024_03092_w crossref_primary_10_1007_s44345_024_00007_3 crossref_primary_10_1007_s10787_023_01171_7 crossref_primary_10_1371_journal_pone_0293682 crossref_primary_10_2147_RRU_S478740 crossref_primary_10_2174_0127722708307894240624105514 crossref_primary_10_1007_s12031_024_02250_2 crossref_primary_10_1016_j_fbio_2023_103539 |
| Cites_doi | 10.1016/j.fct.2017.12.017 10.1016/j.etp.2010.11.001 10.1111/andr.12764 10.5213/inj.2014.18.3.115 10.1186/s12906-015-0825-y 10.1159/000366210 10.1186/s12906-019-2510-z 10.1155/2019/9613090 10.1007/s10787-020-00723-5 10.1007/s00210-020-01991-2 10.1016/j.ajem.2019.04.001 10.1111/j.1439-0272.1998.tb01375.x 10.1002/ptr.5693 10.4103/1008-682X.140966 10.1016/j.ejphar.2020.173631 10.1186/s12906-017-1877-y 10.1016/j.toxlet.2013.03.002 10.1007/s10787-018-0548-z 10.1097/01.ju.0000139539.94828.29 10.1111/jfbc.12987 10.1186/s13046-016-0418-8 10.1016/j.fct.2014.04.012 10.1111/and.13179 10.1016/B978-0-7020-4226-3.00011-1 10.1016/S0006-291X(02)00947-6 10.4103/1008-682X.169997 10.3892/etm.2013.1008 10.1016/0003-9861(59)90090-6 10.1016/j.jep.2016.05.052 10.1016/j.mam.2008.08.006 10.1016/S0021-9258(17)36703-0 10.1007/s11356-020-07817-1 10.1016/j.ejphar.2008.05.043 10.5812/semj.55075 10.1016/j.taap.2016.09.024 10.1016/j.biopha.2018.12.038 10.1016/0076-6879(90)86134-H 10.1002/ptr.2968 10.1038/nrurol.2016.168 10.2147/IJN.S202645 10.1002/pros.10084 10.17795/jjnpp-38177 10.1002/pros.10169 10.1016/S0149-2918(07)80077-4 10.1021/acs.jnatprod.5b01055 10.1016/j.apsb.2012.06.003 10.1016/j.fct.2017.11.025 10.1152/ajpregu.00392.2014 10.1155/2018/1056173 10.1093/jnci/89.1.40 10.1517/14728214.11.1.111 10.1007/s11934-008-0048-6 10.3389/fphar.2017.00234 10.1016/j.ejphar.2019.172729 10.1016/j.eujim.2012.01.004 10.1002/pros.23100 10.3892/etm.2016.3866 10.1155/2018/5164314 10.1177/147323001103900514 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7U7 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA |
| DOI | 10.1186/s12906-021-03472-2 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Toxicology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2662-7671 1472-6882 |
| EndPage | 301 |
| ExternalDocumentID | oai_doaj_org_article_862eca20a1054e32b4d9db482307eb88 PMC8690423 A693609579 34930229 10_1186_s12906_021_03472_2 |
| Genre | Journal Article |
| GeographicLocations | Canada Germany |
| GeographicLocations_xml | – name: Canada – name: Germany |
| GroupedDBID | 53G 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABUWG ADUKV AEUYN AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS BENPR BMC C6C CCPQU EBLON EBS EMB EMOBN FYUFA GROUPED_DOAJ HMCUK IAO IHR IHW INH ITC M1P M~E PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO ROL RPM RSV SOJ SV3 UKHRP AAYXX CITATION ACRMQ C24 CGR CUY CVF ECM EIF NPM PMFND --- 0R~ 23N 2WC 3V. 5VS 6J9 6PF 7TK 7U7 7XB 8FK A8Z AAHBH AAWTL ACGFO ACGFS ACMJI ACPRK ADBBV ADRAZ AENEX AFRAH AHBYD AHMBA AHYZX ALIPV AMKLP AOIJS AZQEC BAWUL BCNDV BFQNJ BPHCQ BVXVI C1K CS3 DIK DU5 DWQXO E3Z F5P GX1 HYE INR K9. KQ8 O5R O5S OVT P2P PKEHL PQEST PQQKQ PQUKI PRINS PROAC RBZ RNS SMD TR2 UNMZH W2D WOQ WOW XSB 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c671t-28a81df834f56d3b3a4ff892ce4f7a4a60140dbcf4f66a56e9648fcc940e32f53 |
| IEDL.DBID | C6C |
| ISSN | 2662-7671 |
| IngestDate | Wed Aug 27 01:31:35 EDT 2025 Tue Sep 30 17:05:35 EDT 2025 Fri Sep 05 03:08:54 EDT 2025 Fri Sep 05 05:31:51 EDT 2025 Mon Jun 30 13:51:44 EDT 2025 Tue Jun 17 21:05:35 EDT 2025 Tue Jun 10 20:39:47 EDT 2025 Thu May 22 21:23:30 EDT 2025 Thu Jan 02 22:45:24 EST 2025 Wed Oct 01 04:29:19 EDT 2025 Thu Apr 24 23:05:25 EDT 2025 Sat Sep 06 07:29:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Inflammation, Rat Berberine Testosterone Oxidative stress BPH |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c671t-28a81df834f56d3b3a4ff892ce4f7a4a60140dbcf4f66a56e9648fcc940e32f53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doi.org/10.1186/s12906-021-03472-2 |
| PMID | 34930229 |
| PQID | 2620954500 |
| PQPubID | 44230 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_862eca20a1054e32b4d9db482307eb88 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8690423 proquest_miscellaneous_2636382687 proquest_miscellaneous_2612378878 proquest_journals_2620954500 gale_infotracmisc_A693609579 gale_infotracacademiconefile_A693609579 gale_healthsolutions_A693609579 pubmed_primary_34930229 crossref_primary_10_1186_s12906_021_03472_2 crossref_citationtrail_10_1186_s12906_021_03472_2 springer_journals_10_1186_s12906_021_03472_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-20 |
| PublicationDateYYYYMMDD | 2021-12-20 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC complementary and alternative medicine |
| PublicationTitleAbbrev | BMC Complement Med Ther |
| PublicationTitleAlternate | BMC Complement Med Ther |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | NNC Tam (3472_CR57) 2003; 55 R Sundaram (3472_CR16) 1999; 4 G Andriole (3472_CR4) 2004; 172 J Miller (3472_CR3) 2009; 4 MS Lucia (3472_CR5) 2008; 9 HM Hussien (3472_CR39) 2018; 111 S Kulkarni (3472_CR31) 2010; 24 J Lin (3472_CR19) 2013; 5 S Gravas (3472_CR2) 2019 MS Othman (3472_CR34) 2014; 69 B Chughtai (3472_CR6) 2011; 13 3472_CR47 J Yin (3472_CR27) 2012; 2 MO Ripple (3472_CR58) 1997; 89 RT Atawia (3472_CR72) 2013; 219 M Imenshahidi (3472_CR22) 2016; 30 IO Kazaz (3472_CR32) 2020; 38 X Wang (3472_CR25) 2018; 2018 M Uygur (3472_CR17) 1998; 30 M Roghani (3472_CR48) 1933; 2020 KT McVary (3472_CR15) 2007; 29 3472_CR51 OA Adaramoye (3472_CR66) 2019; 111 PL Minciullo (3472_CR9) 2015; 94 X Zhao (3472_CR33) 2011; 39 L Peng (3472_CR28) 2015; 8 MM Abdel-Rahman (3472_CR29) 2017; 2 GL Ellman (3472_CR46) 1959; 82 W-Y Jeon (3472_CR11) 2017; 17 H Esterbauer (3472_CR42) 1990; 186 M Kim (3472_CR21) 2014; 18 C Kiriya (3472_CR37) 2019; 43 SM Shoieb (3472_CR60) 2018; 111 L Goldenberg (3472_CR55) 2009; 3 TR Jarvis (3472_CR54) 2015; 17 RH Sayed (3472_CR69) 2016; 311 C De Nunzio (3472_CR8) 2016; 13 TL Bullock (3472_CR18) 2006; 11 N-N Yuan (3472_CR35) 2019; 19 JJ Haddad (3472_CR73) 2002; 296 J Song (3472_CR67) 2020; 8 C Eleazu (3472_CR1) 2017; 8 3472_CR26 H Kalantar (3472_CR43) 2016; 11 P Vital (3472_CR7) 2016; 76 AK Jena (3472_CR49) 2016; 190 C Nathan (3472_CR68) 1994; 269 H Hassani‐Bafrani (3472_CR40) 2019; 51 A Nandi (3472_CR65) 2019; 2019 M Goudarzi (3472_CR45) 2021; 394 G Kramer (3472_CR71) 2002; 52 F Mostafa (3472_CR13) 2019; 865 SR Saleh (3472_CR24) 2018; 2018 SK Kim (3472_CR38) 2015; 15 W Li (3472_CR23) 2016; 12 Y Tian (3472_CR56) 2016; 18 SK Kulkarni (3472_CR30) 2008; 589 G Oktem (3472_CR44) 2012; 64 M Goudarzi (3472_CR52) 2020; 27 B Palmieri (3472_CR63) 2007; 11 RK Ernest (3472_CR41) 1996 RC Tostes (3472_CR59) 2016; 310 M Kalantar (3472_CR53) 2016; 18 L Beneš (3472_CR62) 1999; 65 E Bernt (3472_CR50) 1974 HJ Forman (3472_CR64) 2009; 30 AM Abdel-Aziz (3472_CR70) 2020; 889 B Al-Trad (3472_CR12) 2019; 14 UK Udensi (3472_CR61) 2016; 35 A Elberry (3472_CR14) 2020; 28 A Hamid (3472_CR10) 2011; 43 M Agrawal (3472_CR36) 2012; 4 DJ Newman (3472_CR20) 2016; 79 |
| References_xml | – volume-title: Biochemistry-An Introduction to Dynamic Biology year: 1996 ident: 3472_CR41 – volume: 111 start-page: 650 year: 2018 ident: 3472_CR60 publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2017.12.017 – volume: 64 start-page: 471 issue: 5 year: 2012 ident: 3472_CR44 publication-title: Exp Toxicol Pathol doi: 10.1016/j.etp.2010.11.001 – volume: 8 start-page: 793 issue: 3 year: 2020 ident: 3472_CR67 publication-title: Andrology doi: 10.1111/andr.12764 – volume: 18 start-page: 115 issue: 3 year: 2014 ident: 3472_CR21 publication-title: Int Neurourol J doi: 10.5213/inj.2014.18.3.115 – volume: 3 start-page: S109 issue: 3 Suppl 2 year: 2009 ident: 3472_CR55 publication-title: Can Urol Assoc J – volume: 15 start-page: 380 issue: 1 year: 2015 ident: 3472_CR38 publication-title: BMC Complement Altern Med doi: 10.1186/s12906-015-0825-y – volume: 65 start-page: 1865 issue: 18–19 year: 1999 ident: 3472_CR62 publication-title: Life Sci – volume: 94 start-page: 249 issue: 3 year: 2015 ident: 3472_CR9 publication-title: Urol Int doi: 10.1159/000366210 – volume: 19 start-page: 109 issue: 1 year: 2019 ident: 3472_CR35 publication-title: BMC Complement Altern Med doi: 10.1186/s12906-019-2510-z – volume: 2019 start-page: 9613090 year: 2019 ident: 3472_CR65 publication-title: Oxid Med Cell Longev doi: 10.1155/2019/9613090 – volume: 18 start-page: 62 issue: 7 year: 2016 ident: 3472_CR53 publication-title: Journal of Babol University of Medical Sciences – volume: 28 start-page: 1525 year: 2020 ident: 3472_CR14 publication-title: Inflammopharmacology doi: 10.1007/s10787-020-00723-5 – volume: 11 start-page: 383 issue: 6 year: 2007 ident: 3472_CR63 publication-title: Eur Rev Med Pharmacol Sci – volume: 394 start-page: 523 issue: 3 year: 2021 ident: 3472_CR45 publication-title: Naunyn Schmiedebergs Arch Pharmacol doi: 10.1007/s00210-020-01991-2 – volume: 38 start-page: 33 issue: 1 year: 2020 ident: 3472_CR32 publication-title: Am J Emerg Med doi: 10.1016/j.ajem.2019.04.001 – volume: 30 start-page: 5 issue: 1 year: 1998 ident: 3472_CR17 publication-title: Andrologia doi: 10.1111/j.1439-0272.1998.tb01375.x – volume: 30 start-page: 1745 issue: 11 year: 2016 ident: 3472_CR22 publication-title: Phytother Res doi: 10.1002/ptr.5693 – volume: 17 start-page: 212 issue: 2 year: 2015 ident: 3472_CR54 publication-title: Asian journal of andrology doi: 10.4103/1008-682X.140966 – volume: 889 start-page: 173631 year: 2020 ident: 3472_CR70 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2020.173631 – volume: 17 start-page: 1 issue: 1 year: 2017 ident: 3472_CR11 publication-title: BMC Complement Altern Med doi: 10.1186/s12906-017-1877-y – volume: 219 start-page: 160 issue: 2 year: 2013 ident: 3472_CR72 publication-title: Toxicol Lett doi: 10.1016/j.toxlet.2013.03.002 – ident: 3472_CR26 doi: 10.1007/s10787-018-0548-z – volume: 2 start-page: 1 year: 2017 ident: 3472_CR29 publication-title: Nutr Food Sci Int J – volume: 13 start-page: 147 issue: 3 year: 2011 ident: 3472_CR6 publication-title: Reviews in Urology – volume: 172 start-page: 1399 issue: 4 Part 1 year: 2004 ident: 3472_CR4 publication-title: J Urol doi: 10.1097/01.ju.0000139539.94828.29 – volume: 43 start-page: e12987 issue: 9 year: 2019 ident: 3472_CR37 publication-title: J Food Biochem doi: 10.1111/jfbc.12987 – volume: 35 start-page: 139 issue: 1 year: 2016 ident: 3472_CR61 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-016-0418-8 – volume: 4 start-page: 175 issue: 1 year: 1999 ident: 3472_CR16 publication-title: Asian J Androl – volume: 69 start-page: 175 year: 2014 ident: 3472_CR34 publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2014.04.012 – volume: 2020 start-page: 14 year: 1933 ident: 3472_CR48 publication-title: Drug Des Dev Ther – volume: 51 start-page: e13179 issue: 2 year: 2019 ident: 3472_CR40 publication-title: Andrologia doi: 10.1111/and.13179 – ident: 3472_CR51 doi: 10.1016/B978-0-7020-4226-3.00011-1 – volume: 296 start-page: 847 issue: 4 year: 2002 ident: 3472_CR73 publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(02)00947-6 – volume: 18 start-page: 607 issue: 4 year: 2016 ident: 3472_CR56 publication-title: Asian journal of andrology doi: 10.4103/1008-682X.169997 – volume: 43 start-page: 59 issue: 1 year: 2011 ident: 3472_CR10 publication-title: Acta Med Indones – volume: 5 start-page: 1293 issue: 5 year: 2013 ident: 3472_CR19 publication-title: Exp Ther Med doi: 10.3892/etm.2013.1008 – volume: 82 start-page: 70 issue: 1 year: 1959 ident: 3472_CR46 publication-title: Arch Biochem Biophys doi: 10.1016/0003-9861(59)90090-6 – volume: 190 start-page: 33 year: 2016 ident: 3472_CR49 publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2016.05.052 – volume: 30 start-page: 1 issue: 1–2 year: 2009 ident: 3472_CR64 publication-title: Mol Aspects Med doi: 10.1016/j.mam.2008.08.006 – volume: 269 start-page: 13725 issue: 19 year: 1994 ident: 3472_CR68 publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)36703-0 – volume: 27 start-page: 1 issue: 12 year: 2020 ident: 3472_CR52 publication-title: Environ Sci Pollut Res doi: 10.1007/s11356-020-07817-1 – volume: 589 start-page: 163 issue: 1–3 year: 2008 ident: 3472_CR30 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2008.05.043 – volume-title: Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) year: 2019 ident: 3472_CR2 – ident: 3472_CR47 doi: 10.5812/semj.55075 – volume: 311 start-page: 52 year: 2016 ident: 3472_CR69 publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2016.09.024 – volume: 111 start-page: 403 year: 2019 ident: 3472_CR66 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2018.12.038 – volume: 186 start-page: 407 year: 1990 ident: 3472_CR42 publication-title: Methods Enzymol doi: 10.1016/0076-6879(90)86134-H – volume: 24 start-page: 317 issue: 3 year: 2010 ident: 3472_CR31 publication-title: Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives doi: 10.1002/ptr.2968 – volume: 13 start-page: 613 issue: 10 year: 2016 ident: 3472_CR8 publication-title: Nat Rev Urol doi: 10.1038/nrurol.2016.168 – volume: 14 start-page: 3145 year: 2019 ident: 3472_CR12 publication-title: Int J Nanomed doi: 10.2147/IJN.S202645 – volume: 52 start-page: 43 issue: 1 year: 2002 ident: 3472_CR71 publication-title: Prostate doi: 10.1002/pros.10084 – volume: 11 start-page: e38177 issue: 3 year: 2016 ident: 3472_CR43 publication-title: Jundishapur Journal of Natural Pharmaceutical Products doi: 10.17795/jjnpp-38177 – volume: 55 start-page: 1 issue: 1 year: 2003 ident: 3472_CR57 publication-title: Prostate doi: 10.1002/pros.10169 – volume: 29 start-page: 387 issue: 3 year: 2007 ident: 3472_CR15 publication-title: Clin Ther doi: 10.1016/S0149-2918(07)80077-4 – volume: 79 start-page: 629 issue: 3 year: 2016 ident: 3472_CR20 publication-title: J Nat Prod doi: 10.1021/acs.jnatprod.5b01055 – volume: 2 start-page: 327 issue: 4 year: 2012 ident: 3472_CR27 publication-title: Acta Pharmaceutica Sinica B doi: 10.1016/j.apsb.2012.06.003 – volume: 111 start-page: 432 year: 2018 ident: 3472_CR39 publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2017.11.025 – volume: 310 start-page: R1 issue: 1 year: 2016 ident: 3472_CR59 publication-title: American Journal of Physiology-Regulatory, Integrative and Comparative Physiology doi: 10.1152/ajpregu.00392.2014 – volume: 2018 start-page: 1056173 year: 2018 ident: 3472_CR24 publication-title: Oxid Med Cell Longev doi: 10.1155/2018/1056173 – volume: 89 start-page: 40 issue: 1 year: 1997 ident: 3472_CR58 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/89.1.40 – volume: 11 start-page: 111 issue: 1 year: 2006 ident: 3472_CR18 publication-title: Expert Opin Emerg Drugs doi: 10.1517/14728214.11.1.111 – volume: 9 start-page: 272 issue: 4 year: 2008 ident: 3472_CR5 publication-title: Curr Urol Rep doi: 10.1007/s11934-008-0048-6 – volume: 8 start-page: 234 year: 2017 ident: 3472_CR1 publication-title: Front Pharmacol doi: 10.3389/fphar.2017.00234 – start-page: 1506 volume-title: Methods of enzymatic analysis year: 1974 ident: 3472_CR50 – volume: 865 start-page: 172729 year: 2019 ident: 3472_CR13 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2019.172729 – volume: 4 start-page: e177 issue: 2 year: 2012 ident: 3472_CR36 publication-title: European Journal of Integrative Medicine doi: 10.1016/j.eujim.2012.01.004 – volume: 76 start-page: 58 issue: 1 year: 2016 ident: 3472_CR7 publication-title: Prostate doi: 10.1002/pros.23100 – volume: 12 start-page: 4041 issue: 6 year: 2016 ident: 3472_CR23 publication-title: Exp Ther Med doi: 10.3892/etm.2016.3866 – volume: 2018 start-page: 5164314 year: 2018 ident: 3472_CR25 publication-title: Evidence-Based Complementary and Alternative Medicine doi: 10.1155/2018/5164314 – volume: 8 start-page: 5217 issue: 5 year: 2015 ident: 3472_CR28 publication-title: Int J Clin Exp Pathol – volume: 39 start-page: 1720 issue: 5 year: 2011 ident: 3472_CR33 publication-title: J Int Med Res doi: 10.1177/147323001103900514 – volume: 4 start-page: 251 year: 2009 ident: 3472_CR3 publication-title: Clin Interv Aging |
| SSID | ssj0002313735 ssj0017814 |
| Score | 2.2669854 |
| Snippet | Introduction
Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence... Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence... Introduction Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence... INTRODUCTION: Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence... Abstract Introduction Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 301 |
| SubjectTerms | Acids Anesthesia Animals Anti-inflammatory agents Anti-Inflammatory Agents - pharmacology Antioxidants Antioxidants - pharmacology Berberine Berberine - pharmacology blood serum BPH Catalase cervical dislocation Chiropractic Medicine complement Complementary & Alternative Medicine Cytokines Depletion Dihydrotestosterone Dihydrotestosterone - blood Disease Models, Animal Drugs, Chinese Herbal - pharmacology Finasteride Finasteride - pharmacology Genital diseases histology histopathology Hyperplasia Inflammation Inflammation, Rat ingredients Interleukin-1beta - drug effects Interleukins Internal Medicine Laboratory animals Lipid peroxidation Lipids Male Males Medicine Medicine & Public Health nitrites Olive oil Oxidative stress Oxidative Stress - drug effects Peroxidation Prostate Prostate - drug effects Prostatic Hyperplasia - drug therapy Proteins Rats Rats, Wistar Superoxide Superoxide dismutase Testosterone Testosterone - blood Tumor Necrosis Factor-alpha - drug effects Tumor necrosis factor-TNF Tumor necrosis factor-α tumor necrosis factors Urogenital system |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2ggJGQOIDVxO8cW0RVIbUnKvVm2Y5NF7Xpqrv9_8w42bApoly4rseS83nGM7Oe-UzIh1rHpg5NxzIkQEwGm1krOsPQFSnwx0aXDrnjE310Kr-dqbOtp76wJmygBx6A24OIO0XPaw-BgEyCB9m1XZB4P2RSsKXNF9zYVjL1s5C4NMIItemSsXpvhX-4YL0tVhBJwxmfeaJC2P_nsbzll27XTN66OC3-6PAReTgGknR_-IDH5F7qn5D7x-NV-VNycgCAld4-6i_TBXbiQ1RJ1_iSDJIjXPWJQT4OO9vRkPrFj54usQMEpOg5JKfXy9JgSRc9hZmrZ-T08Ov3L0dsfDyBRW2aNePWQyiarZBZ6U4E4WXOtuUxyWy89BpTqy7ELLPWXunUamlzjK2sAeWsxHOy08NSXhIK-JtOSJWjqmXiKiBhjml857mHw9RXpNkA6eLILI4PXFy4kmFY7QbwHYDvCviOV-TTNGc58GrcKX2A-zNJIid2-QE0xY2a4v6lKRV5h7vrhgbTybLdvm4F0u6ZtiIfiwTaNnxA9GOLAsCALFkzyd2ZJNhknA9vNMiNZ8LKIfV_CwFrXVfk_TSMM7HOrU9XNygDkQQWeNq7ZAQcmlxbU5EXg1JOwAjZCojKYAFmpq4z5OYj_eK8sIrj02QQW1fk80axfy_97zvz6n_szGvygKNhNmCV9S7ZWV_fpDcQ663D22LWvwDNLEyO priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQw0IIiIS6IN4ECQULiAFET27GdE2oRVYXUnqi0N8vPdqU2u-xu_58Zx5uSIvYajyV73hPPg5BPtXBNbRtfRQiAKm5VrDrmZYWmqAV7LEWqkDs9Eyfn_OesneUfbuucVrnViUlR-4XDf-QH2Di9A3Nf19-WvyucGoWvq3mExn3yoAFXBblazsaAq8F2TttCGSUO1vjPBVNuMYmIS1rRiTFKPfv_1cx_maa7aZN33k6TSTp-Qh5nX7I8HIj_lNwL_TPy8DS_lj8nZ0eAs1TeV5rrcIXF-OBYlhscJoP9ERZ9qCAkB-L60oZ-ftGXSywCAajyEuLT1TLVWJbzvoSd6xfk_PjHr-8nVZ6fUDkhm01FlQFvNCrGYys8s8zwGFVHXeBRGm4ERlfeusijEKYVoRNcRec6XgdGY8tekr0ejvKalMEZ6Rlvo2trHmhrsWeObIw31IA-NQVptojULjcXxxkXVzoFGUroAfkakK8T8jUtyJdxz3JorbET-gjpM0JiW-z0YbG60FnKNIRncFJaG_AaOdzBct95y_ExUQarVEE-IHX1UGM6Crc-FB3DznuyK8jnBIHiDRdwJlcpABqwUdYEcn8CCWLppstbDtJZLaz1LRMX5OO4jDsx1a0PixuEAWcCczzVLhgGepMKJQvyamDKETGMdwwcMziAnLDrBHPTlX5-mRqL43QycK8L8nXL2LdH_z9l3uy-6VvyiKLINSBv9T7Z26xuwjtw5Db2fZLWP3gmQ8M priority: 102 providerName: ProQuest |
| Title | Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats |
| URI | https://link.springer.com/article/10.1186/s12906-021-03472-2 https://www.ncbi.nlm.nih.gov/pubmed/34930229 https://www.proquest.com/docview/2620954500 https://www.proquest.com/docview/2612378878 https://www.proquest.com/docview/2636382687 https://pubmed.ncbi.nlm.nih.gov/PMC8690423 https://doaj.org/article/862eca20a1054e32b4d9db482307eb88 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017814 issn: 2662-7671 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017814 issn: 2662-7671 databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017814 issn: 2662-7671 databaseCode: KQ8 dateStart: 20010501 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017814 issn: 2662-7671 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017814 issn: 2662-7671 databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: Geneva Foundation for Medical Education and Research Open Access Journals customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017814 issn: 2662-7671 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: RPM dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 2662-7671 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002313735 issn: 2662-7671 databaseCode: C6C dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxQxEA_agvgifrtazxUEH3RxN9_72DtaitBDioXDl5Bkk_agbo_e9f93Jru3dqsWfLmHywSy85WZZOYXQj6U0lelq5oiQgJUcKdjUbNGFbgVCdiPlUwdcsdzeXTKvy7EoofJwV6Ym_f3lZZf1nhOgmWyWPjDFS3A3e4KcLxYvjeTs-E8BeIUppjY9sX8depo70kQ_X864hs70e0qyVtXpWkHOnxMHvWhY77fyfoJuRfap-TBcX85_ozMp8Ci1M2X25_hAnvvIY7MN_h2DMIhXLahgAwcZNnkLrTLszZfYc8HUOXnkI5erVJLZb5sc5i5fk5ODw--z46K_rmEwktVbQqqLQSfUTMehWyYY5bHqGvqA4_KcisxmWqcjzxKaYUMteQ6el_zMjAaBXtBdlpYyiuSB29Vw7iIXpQ8UOEQIkdVtrHUgvu0Gam2jDS-xxLHJy0uTMoptDQd8w0w3yTmG5qRT8OcVYekcSf1FOUzUCIKdvoDlMP0RmUgG4OV0tJCkMjhGxxv6sZxvDtUwWmdkXcoXdO1lA62bPZlzRBoT9UZ-Zgo0JrhA7ztmxKADYiLNaLcG1GCFfrx8FaDTO8F1gbB_msIUcsyI--HYZyJlW1tuLxGGogdsKRT30XDwE1SqVVGXnZKOTCG8ZpBHAYLUCN1HXFuPNIuzxOOOD5GBtF0Rj5vFfv30v8tmdf_R_6GPKRoghXYX7lHdjZX1-EtxHEbNyH31UJNyO70YP7tZJLMeZLOROD3ZPpjko7efgHJXELI |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXxLuBQoME4gBRE9uxnQNCLVBtaXdPrbQ34zh2u1LJLrtbIf4Uv5EZJ9mSIvbWazyW7PF4HvHMN4S8ToXN0jKrEg8BUMJL5ZOCVTJBU5SDPZYiVMgNR2Jwyr-O8_EG-d3VwmBaZacTg6Kuphb_ke8icHoB5j5NP85-JNg1Cl9XuxYajVgcuV8_IWRbfDj8DOf7htKDLyefBknbVSCxQmbLhCoDPppXjPtcVKxkhnuvCmod99JwIzDmqErruRfC5MIVgitvbcFTx6jHLhGg8m9xlnLE6pfjVYCXIXxUV5ijxO4C__Fgii8mLXFJE9ozfqFHwL-W4C9TeD1N89pbbTCBB_fJvdZ3jfcaYXtANlz9kNwetq_zj8hoH84olBPG5ru7wOJ_cGTjJTavQTyGae2SSV2BMFVx6erJWR3PsOgEqOJziIfns1DTGU_qGGYuHpPTG-HsE7JZw1K2SOyskRXjubd5yh3NS8TokZmpDDWgv01Eso6R2rZg5thT40KHoEYJ3TBfA_N1YL6mEXm3mjNroDzWUu_j-awoEYY7fJjOz3R7qzWEg7BSmhrwUjnsoeRVUZUcHy-lK5WKyA6erm5qWlfKRO-JgiHSnywi8jZQoDqBDVjTVkUAGxCYq0e53aMENWD7w50E6VYNLfTVpYnIq9UwzsTUutpNL5EGnBfMKVXraBjoaSqUjMjTRihXjGG8YOAIwgJkT1x7nOuP1JPzAGSO3dDAnY_I-06wr5b-_5N5tn6nO-TO4GR4rI8PR0fPyV2K1y-Du5duk83l_NK9ACdyWb4MNzcm325aVfwBlGWBTQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDI_QJk28IL4pDFYkJB6gWtt8P96A0zjYCQkm7S1K02Q7afROd7f_Hzv9YB0widfGkRLHduzG_pmQN7lwRV4VdRYgAMpYpUKmaS0zvIo43MdSxAq5k7k4PmWzM352rYo_Zrv3T5JtTQOiNDXbw1UdWhVX4nCDf08weRbTgZgsMzDCu4prAeHX7mQy-z4b_rOA_0Il5X29zF8nj-6kCN3_p4G-dkPdzJ688YQab6bpfXKvcynTSSsDD8gd3zwkeyfdo_kjMj8C1sUqv9T-9JdYkw_-ZbrFnjIIk7BsfAaROZxxnVa-WZw36QprQYAqvYAwdb2KpZbpoklh5uYxOZ1--vHhOOvaKGROyGKblcqCUxoUZYGLmlbUshCULp1nQVpmBQZZdeUCC0JYLrwWTAXnNMs9LQOnT8hOA0t5RlLvrKwp48HxnPmSVwidIwtb29KCWbUJKXpGGtdhjGOri0sTYw0lTMt8A8w3kfmmTMi7Yc6qRdi4lfoIz2egRHTs-GG5PjedshmI0mClZW7BeWSwh4rVuq4YvilKXymVkAM8XdOWmg46biZCUwTgkzohbyMFajlswNmuWAHYgHhZI8r9ESVopxsP9xJkOuuwMdgEQIPrmucJeT0M40zMeGv88gppwKfAVE91Gw0F81kKJRPytBXKgTGUaQr-GSxAjsR1xLnxSLO4iPji2KQMvOyEvO8F-_fS_30yz_-P_IDsffs4NV8_z7-8IHdL1MYCVDHfJzvb9ZV_Ca7etnrVafMvcqVJ3g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Berberine+ameliorates+testosterone-induced+benign+prostate+hyperplasia+in+rats&rft.jtitle=BMC+complementary+medicine+and+therapies&rft.au=Shabani%2C+Ehsan&rft.au=Kalantari%2C+Heibatullah&rft.au=Kalantar%2C+Mojtaba&rft.au=Goudarzi%2C+Mehdi&rft.date=2021-12-20&rft.pub=BioMed+Central&rft.eissn=2662-7671&rft.volume=21&rft_id=info:doi/10.1186%2Fs12906-021-03472-2&rft_id=info%3Apmid%2F34930229&rft.externalDocID=PMC8690423 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2662-7671&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2662-7671&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2662-7671&client=summon |